§ Claim under review · Health
"Scientists Found a Switch That Turns Off Fat Storage — And Turns On Fat Burning." Researchers at the Weizmann Institute silenced the MTCH2 ("Mitch") protein in human cells, triggering rapid fat/carb burning, blocking immature cells from becoming fat-storing cells, and offering a pathway for obesity therapies that spare muscle.
Verdict
Source exists but framing is misleading
Confidence
HighSummary
The study cited in this Instagram post is real. Researchers at the Weizmann Institute of Science, led by Prof. Atan Gross, published a 2025 paper in EMBO Journal showing that deleting the MTCH2 ("Mitch") protein in cultured cells increases energy burning, disrupts mitochondrial fusion, and prevents preadipocyte cells from becoming mature fat cells. However, the post overstates what was shown in humans: the metabolic results came from a human cancer cell line (HeLa), while the "blocked fat-cell development" result came from mouse preadipocytes, not human adipocytes. The claim that cells "become immune to obesity" and the framing of MTCH2 as a ready therapeutic "switch" that spares muscle are extrapolations from earlier mouse experiments, not from human data. No drug exists, no human trial has been conducted, and the researchers themselves describe this as an early mechanistic finding. The science is genuine, but the viral framing pushes it well beyond what the evidence supports.
The readings
key figures from the evidenceEMBO Journal volume/issue/pages of the cited study
Why this verdict
Evidence
The cited paper is real and correctly identified. Mitochondrial carrier homolog 2 (MTCH2) is a regulator of apoptosis, mitochondrial dynamics, and metabolism. Loss of MTCH2 results in mitochondrial fragmentation, an increase in whole-body energy utilization, and protection against diet-induced obesity.
In the new work, the researchers used temporal metabolomics on HeLa cells to show that MTCH2 deletion results in altered metabolism. In parallel, targeted metabolomics of the MTCH2 knockout NIH3T3L1 preadipocytes showed higher levels of NAD+, NADP+, and a higher AMP/ATP ratio, indicating an oxidative and low-energy environment, which is not favorable for differentiation.
Importantly, MTCH2 knockout cells showed an increase in mitochondrial oxidative function, which may explain the higher energy demand.
Interestingly, this imbalance in energy metabolism and reductive potential triggered by MTCH2-deletion prevents NIH3T3L1 preadipocytes from differentiating into mature adipocytes, an energy consuming reductive biosynthetic process.
The mitochondrial-fusion mechanism referenced in the post is also grounded in the paper: it was recently reported that MTCH2 regulates mitochondrial fusion by modulating the pro-mitochondrial fusion lipid lysophosphatidic acid (LPA).
The earlier animal work cited by the post is real. According to the Weizmann press release, when he and his team silenced the expression of the MTCH2 protein, dubbed "Mitch," in muscles of mice, these mice developed increased athletic capacity and were "immune" to obesity, thanks to an accelerated rate of metabolism.
Independent coverage confirms the framing that a 2025 study points to a protein with a weirdly appropriate nickname: Mitch. In human cells, disabling the protein, formally called MTCH2, pushed cells to burn more fuel and made it harder for new fat cells to form. That same coverage adds a critical qualifier omitted from the Instagram post: the work is early and far from a treatment .
Findings
✓ What's accurate 6
- The paper, authors, journal, volume, and DOI cited in the post are accurate.
- The nickname "Mitch" for MTCH2 is genuine and used by the Weizmann team.
- Silencing MTCH2 does increase energy demand and reduce mitochondrial fusion in the cell systems tested.
- MTCH2 deletion did prevent preadipocytes from differentiating into mature fat cells.
- Prior mouse studies did show MTCH2-deficient mice resistant to diet-induced obesity with enhanced athletic capacity.
- GLP-1 agonists are widely reported to cause some lean mass loss alongside fat loss, and the researchers themselves frame their work in that context.
≈ What's misleading 4
- **Species/system elision (subgroup generalization):** The post says researchers "used genetic engineering to silence the protein in human cells" and that the block on fat-cell differentiation makes "them" (implied: people) "immune to obesity." The differentiation-blocking result was demonstrated in mouse NIH3T3-L1 preadipocytes, not human adipocytes. The human-cell work (HeLa) established metabolic changes, not immunity to obesity.
- **Temporal overreach / marketing framing:** Calling MTCH2 a "switch" that "turns off fat storage" and describing a "rapid, permanent state of cellular energy demand" overstates a mechanistic finding in cultured cells. "Permanent" is not language from the paper; it describes what happens when the gene is genetically knocked out, which is not equivalent to any available therapy.
- **Omitted qualifier:** The Instagram post presents the finding as a "promising pathway for next-generation obesity therapies" without noting that no drug, small molecule, or human trial exists; the work is preclinical.
- **"Sparing or even strengthening muscle tissue":** The paper does not demonstrate muscle sparing or strengthening in humans. That framing is extrapolated from the earlier mouse studies where muscle-specific MTCH2 knockout produced athletic mice.
? What's uncertain 2
- Whether any druggable MTCH2 inhibitor exists or is in development. No such candidate is described in the paper.
- Whether whole-body MTCH2 inhibition in humans would be safe: MTCH2 also regulates apoptosis and mitochondrial dynamics, so systemic effects are unclear and not addressed in the viral post.
Sources
1 of 4 linked to recordsChourasia et al., "MTCH2 controls energy demand and expenditure to fuel anabolism during adipogenesis," *EMBO Journal* 44(4):1007–1038 (2025), DOI: 10.1038/s44318-024-00335-7
Weizmann Wonder Wander press release "Slimming with Mitch" (wis-wander.weizmann.ac.il)
bioRxiv preprint of the same work (Dec 2023)
Secondary coverage: ScienceAlert, ZME Science, ScienceDaily, Technology Networks, NewsNation